"HBY-097, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Limits Acute HIV-1 Infection in an In Vitro Hollow Fiber Pharmacodynamic Model System."

According to an abstract submitted by the authors to the 37th ICAAC, held September 28 - October 1, 1997, in Toronto, Ontario, Canada, "Preliminary data indicated that the quinoxaline NNRTI, HBY-097 was bound to both albumin (ALB) and (alpha)₁ -acid glycoprotein (AGP). In order for us to most rapidly compare the efficacy of a dose of HBY-097 in the presence of plasma proteins, we modeled the multidose human pharmacokinetic data from each patient using the programs in the ADAPT II software package. The plasma HBY-097 concentrations at the trough were calculated for several doses. Initial studies had indicated that the trough concentration for the 750 mg TID dose (1.284 ug...

Want to see the full article?

• Purchase this article for only $3.00